Study probes why IBD meds work better for some groups

NCT ID NCT06266663

Recruiting now Knowledge-focused Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study surveys 400 adults with inflammatory bowel disease (IBD) from two medical centers to understand how social factors like insurance, income, and support affect medication adherence and quality of life. Researchers focus on Hispanic and Black patients, who often have worse outcomes than white patients. The goal is to find modifiable social barriers that can be targeted in future interventions to promote health equity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could identify social factors that help explain why some racial/ethnic groups with IBD have worse outcomes, pointing toward ways to improve care and health equity.
What could go wrong: This is an observational survey, not a treatment trial. It will not directly change outcomes, and findings may not apply to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease indeterminate colitis inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATORY BOWEL DISEASES

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Montefiore Hutchinson Campus
RECRUITING

The Bronx, New York, 10461, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.